MCID: INT025
MIFTS: 44

Intermittent Explosive Disorder malady

Category: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs

Aliases & Classifications for Intermittent Explosive Disorder

About this section

Aliases & Descriptions for Intermittent Explosive Disorder:

Name: Intermittent Explosive Disorder 10 12 65
 
Explosive Personality Disorder 10 65

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 27


External Ids:

Disease Ontology10 DOID:12401
ICD1027 F60.3, F63.81
ICD9CM29 301.3, 312.34
MeSH36 D007174
NCIt42 C94332
UMLS65 C0021776, C0152183

Summaries for Intermittent Explosive Disorder

About this section
Disease Ontology:10 An impulse control disorder that involves the episodic inability to control violent impulses with a disproportionate degree of aggressiveness.

MalaCards based summary: Intermittent Explosive Disorder, also known as explosive personality disorder, is related to pyromania and multiple personality disorder. An important gene associated with Intermittent Explosive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways are Sympathetic Nerve Pathway (Pre- and Post- Ganglionic Junction) and Sympathetic Nerve Pathway (Neuroeffector Junction). Affiliated tissues include prostate, brain and lung, and related mouse phenotypes are skeleton and growth/size/body region.

Wikipedia:68 Intermittent explosive disorder (sometimes abbreviated as IED) is a behavioral disorder characterized by... more...

Related Diseases for Intermittent Explosive Disorder

About this section

Diseases related to Intermittent Explosive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 89)
idRelated DiseaseScoreTop Affiliating Genes
1pyromania23.5ADRB1, CGA, CHRFAM7A, CHRNA7, CTSH, HTR1A
2multiple personality disorder10.7HTR2A, SLC6A4
3vogt-koyanagi-harada disease10.7HTR2A, SLC6A4
4neurodegeneration with optic atrophy, childhood onset10.7HTR2A, SLC6A4
5kluver-bucy syndrome10.7HTR2A, SLC6A4
6prostate adenocarcinoma10.7HTR2A, SLC6A4
7exostosis10.7HTR2A, SLC6A4
8tinea pedis10.6HTR2A, SPG21
9perrault syndrome10.6HTR2A, SLC6A4
10dyserythropoietic anemia, congenital, type ia10.5CHRFAM7A, CHRNA7
11cavernous sinus meningioma10.5HTR2A, TPH1
12zebra body myopathy10.5HTR2A, SLC6A4
13tongue cancer10.5HTR1A, HTR2A
14nelson syndrome10.4HTR1A, HTR2A
15hereditary myopathy with lactic acidosis due to iscu deficiency10.4HTR1A, SLC6A4
16alcoholic hepatitis10.4HTR1B, HTR2A, SLC6A4
17atypical depressive disorder10.4HTR2A, SLC6A4
18progressive locomotor ataxia10.4HTR1A, SLC6A4
19liver leiomyoma10.4HTR2A, HTR7
20coronary thrombosis10.3HTR2A, HTR7
21brachial plexus neoplasm10.3HTR1A, HTR2A, SLC6A4
22steatorrhea10.3HTR2A, HTR7
23geniculate herpes zoster10.3HTR1A, HTR2A, SLC6A4
24hantavirus pulmonary syndrome10.3HTR1A, HTR2A
25ovarian mixed germ cell neoplasm10.3HTR1A, HTR2A, SLC6A4
26neonatal myasthenia gravis10.3HTR1A, HTR2A, SLC6A4
27malignant hyperthermia10.3HTR1A, HTR2A, SLC6A4
28ulcerative blepharitis10.3HTR1A, SLC6A4
29bladder lateral wall cancer10.2HTR2A, HTR7
30c1 inhibitor deficiency10.2HTR2A, HTR7
31tympanosclerosis10.2HTR2A, HTR7, SLC6A4
32marasmus10.2HTR2A, HTR7, SLC6A4
33choledochal cyst10.2CTSH, HTR2A, TPH1
34personality disorder10.1
35lactocele10.1HTR2A, HTR7
36nocardiosis10.1HTR2A, NPY
37sudden infant death syndrome10.1HTR1A, HTR2A, SLC6A4
38autoimmune hepatitis10.1HTR2A, HTR7, SLC6A4
39lymphadenitis10.1CGA, HTR1A, HTR2A, SLC6A4
40parkinsonism-dystonia, infantile10.1CHRNA7, HTR2A, SLC6A4, TPH1
41phonagnosia10.0HTR2A, HTR7
42testicular brenner tumor10.0HTR2A, TPH1
43gastric pylorus carcinoma10.0HTR1B, HTR2A, HTR7
44tick infestation10.0HTR2A, HTR7
45chronic mucocutaneous candidiasis10.0HTR2A, NPY, SLC6A4
46bipolar ll disorder10.0HTR2A, HTR7, TPH1
47acatalasemia10.0HTR2A, NPY, SLC6A4
48diplegia of upper limb10.0HTR2A, HTR7, TPH1
49transient arthritis9.9HTR2A, NPY, SLC6A4
50uterine corpus adenomatoid tumor9.9HTR1A, HTR1B, HTR2A, SLC6A4

Comorbidity relations with Intermittent Explosive Disorder via Phenotypic Disease Network (PDN):


Alzheimer DiseaseSchizophreniform Disorder
Acute Cystitis

Graphical network of the top 20 diseases related to Intermittent Explosive Disorder:



Diseases related to intermittent explosive disorder

Symptoms for Intermittent Explosive Disorder

About this section

Drugs & Therapeutics for Intermittent Explosive Disorder

About this section

Drugs for Intermittent Explosive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Guanfacineapproved, investigationalPhase 45329110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine
Guanfacine (INN)
Guanfacine Hydrochloride
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tenex
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
2
Naratriptanapproved, investigationalPhase 414143388-64-1, 121679-13-84440
Synonyms:
121679-13-8
AC-5013
AC1L1I6A
Amerge
Amerge, Naramig,Naratriptan
BIDD:GT0312
C07792
CHEBI:7478
CHEMBL1278
CID4440
Colatan
D08255
DB00952
InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H
L000432
 
LS-83062
MolPort-005-932-823
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
NCGC00181786-01
Naramig
Naramig (TN)
Naratriptan
Naratriptan (INN)
Naratriptanum
S1488_Selleck
UNII-QX3KXL1ZA2
naratriptan
naratriptanum
3Serotonin AgentsPhase 4, Phase 3, Phase 22668
4Neurotransmitter AgentsPhase 4, Phase 3, Phase 214795
5
SerotoninPhase 4, Phase 3, Phase 2314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
6Contraceptives, OralPhase 43734
7Adrenergic AgentsPhase 44204
8Adrenergic alpha-2 Receptor AgonistsPhase 4790
9Adrenergic alpha-AgonistsPhase 41300
10Antihypertensive AgentsPhase 43618
11Adrenergic AgonistsPhase 42331
12Vasoconstrictor AgentsPhase 41303
13
Risperidoneapproved, investigationalPhase 3477106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
 
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperdal M-tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone M-tab
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
14
DopamineapprovedPhase 3308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
15Tranquilizing AgentsPhase 33597
16Psychotropic DrugsPhase 3, Phase 25501
17Serotonin AntagonistsPhase 31175
18Dopamine AntagonistsPhase 3927
19Antipsychotic AgentsPhase 32130
20Central Nervous System DepressantsPhase 310016
21Dopamine AgentsPhase 33084
22
FluoxetineapprovedPhase 222954910-89-33386
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
AKOS003663021
Adofen
Animex-On
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
Bio-0787
Biomol-NT_000152
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
Fluoxetine
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetine [USAN:INN:BAN]
Fluoxetinum
 
Fluoxetinum [INN-Latin]
Fluoxétine
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
LS-31040
Lilly-110140
Lopac0_000558
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
SPBio_001815
SPBio_002382
STK734483
Sarafem
SpecPlus_000723
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
Spectrum_001679
TL8003595
UNII-01K63SUP8D
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
fluoxetine
fluoxetine (Prozac)
nchembio.534-comp2
23Neurotransmitter Uptake InhibitorsPhase 22857
24Antidepressive Agents, Second-GenerationPhase 21087
25Antidepressive AgentsPhase 22367
26Serotonin Uptake InhibitorsPhase 21369
27Cytochrome P-450 Enzyme InhibitorsPhase 23036
28Cytochrome P-450 CYP2D6 InhibitorsPhase 2602
29SRX246Phase 1, Phase 25
30VasopressinsPhase 1, Phase 2260
31HormonesPhase 1, Phase 211748
32Arginine VasopressinPhase 1, Phase 2264
33Natriuretic AgentsPhase 1, Phase 21403

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive DisorderRecruitingNCT02048241Phase 4
2Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment OrderTerminatedNCT00282165Phase 4
3Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.CompletedNCT00399698Phase 3
4Psychotherapy for Intermittent Explosive DisorderCompletedNCT00667212Phase 2
5A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive DisorderCompletedNCT00078754Phase 2
6A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IEDCompletedNCT00127400Phase 2
7Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive DisorderActive, not recruitingNCT02055638Phase 1, Phase 2

Search NIH Clinical Center for Intermittent Explosive Disorder

Genetic Tests for Intermittent Explosive Disorder

About this section

Anatomical Context for Intermittent Explosive Disorder

About this section

MalaCards organs/tissues related to Intermittent Explosive Disorder:

33
Prostate, Brain, Lung, Endothelial, Tongue, B cells, Testes

Animal Models for Intermittent Explosive Disorder or affiliated genes

About this section

MGI Mouse Phenotypes related to Intermittent Explosive Disorder:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053907.6ADRB1, CHRNA7, HTR1B, HTR2A, NPY, SMOC1
2MP:00053786.8ADRB1, CGA, CHRNA7, CTSH, HTR1B, NPY
3MP:00053866.7CHRNA7, HTR1A, HTR1B, HTR2A, HTR7, NPY

Publications for Intermittent Explosive Disorder

About this section

Articles related to Intermittent Explosive Disorder:

(show top 50)    (show all 75)
idTitleAuthorsYear
1
Prevalence of DSM-IV Intermittent Explosive Disorder in Black Adolescents: Findings From the National Survey of American Life, Adolescent Supplement. (27078052)
2016
2
Amygdala hyperactivation to angry faces in intermittent explosive disorder. (27145325)
2016
3
White Matter Integrity Reductions in Intermittent Explosive Disorder. (27206265)
2016
4
Single Case Study: Neuropsychological Functioning in a Patient Diagnosed with Intermittent Explosive Disorder Pre and Post Neurosurgery. (27161981)
2016
5
Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder. (26277033)
2015
6
Verbal versus physical aggression in Intermittent Explosive Disorder. (25534757)
2015
7
The coherence and correlates of intermittent explosive disorder amongst West Papuan refugees displaced to Papua New Guinea. (25754605)
2015
8
Emotional intelligence and impulsive aggression in Intermittent Explosive Disorder. (25477263)
2015
9
The experience of aggressive outbursts in Intermittent Explosive Disorder. (25541537)
2015
10
Doing Psychiatry Right: A Case of Severe Avoidant Personality Disorder with Obsessive-compulsive Personality Disorder, Obsessive Compulsive Disorder, Intermittent Explosive Disorder and Sexual Paraphilias. (25035563)
2014
11
Emotion regulation deficits in intermittent explosive disorder. (25403171)
2014
12
Self-harm behavior among individuals with intermittent explosive disorder and personality disorders. (25300440)
2014
13
Intermittent explosive disorder: associations with PTSD and other Axis I disorders in a US military veteran sample. (24907536)
2014
14
Common and distinct neural correlates of inhibitory dysregulation: stroop fMRI study of cocaine addiction and intermittent explosive disorder. (25106072)
2014
15
Relationship between psychopathy, aggression, anger, impulsivity, and intermittent explosive disorder. (24760575)
2014
16
Validity of the new A1 and A2 criteria for DSM-5 intermittent explosive disorder. (24321204)
2014
17
Elevated Plasma Oxidative Stress Markers in Individuals with Intermittent Explosive Disorder and Correlation with Aggression in Humans. (24582164)
2014
18
Achieving convergence between a community-based measure of explosive anger and a clinical interview for intermittent explosive disorder in Timor-Leste. (23835102)
2013
19
Elevated Plasma Inflammatory Markers in Individuals With Intermittent Explosive Disorder and Correlation With Aggression in Humans. (24352431)
2013
20
Intermittent explosive disorder amongst women in conflict affected Timor-Leste: associations with human rights trauma, ongoing violence, poverty, and injustice. (23950885)
2013
21
The prevalence and correlates of intermittent explosive disorder in Iraq. (22443168)
2012
22
Intermittent explosive disorder in the National Comorbidity Survey Replication Adolescent Supplement. (22752056)
2012
23
Epidemiological aspects of intermittent explosive disorder in Japan; prevalence and psychosocial comorbidity: findings from the World Mental Health Japan Survey 2002-2006. (20709410)
2011
24
Treating intermittent explosive disorder. Emerging data show medication and cognitive behavioral therapy may help some patients. (21786470)
2011
25
Latent structure of intermittent explosive disorder in an epidemiological sample. (20064645)
2010
26
A case of intermittent explosive disorder. (21694793)
2010
27
Expert witness claimed that a defendant had "intermittent explosive disorder," GMC hears. (21147742)
2010
28
Inverse relationship between numbers of 5-HT transporter binding sites and life history of aggression and intermittent explosive disorder. (19767013)
2010
29
Intermittent explosive disorder in South Africa: prevalence, correlates and the role of traumatic exposures. (19225243)
2009
30
A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. (19389333)
2009
31
P3a and mismatch negativity in individuals with moderate Intermittent Explosive Disorder. (19463896)
2009
32
The relationship between impulsive verbal aggression and intermittent explosive disorder. (17654692)
2008
33
Cognitive-behavioral therapy for intermittent explosive disorder: a pilot randomized clinical trial. (18837604)
2008
34
Lifetime and 12-month intermittent explosive disorder in Latinos. (18444735)
2008
35
EEG correlates of moderate intermittent explosive disorder. (18032100)
2008
36
Intranasal ketamine for intermittent explosive disorder: a case report. (17854260)
2007
37
Intermittent explosive disorder-integrated research diagnostic criteria: convergent and discriminant validity. (16153657)
2006
38
Intermittent explosive disorder and impulsive aggression: the time for serious study is now. (14738696)
2004
39
Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. (15291659)
2004
40
Intermittent explosive disorder: epidemiology, diagnosis and management. (12096933)
2002
41
Psychological characteristics of aggressive drivers with and without intermittent explosive disorder. (12375724)
2002
42
Intermittent explosive disorder and other psychiatric comorbidity among court-referred and self-referred aggressive drivers. (12051483)
2002
43
Validation of the Interview Module for Intermittent Explosive Disorder (M-IED) in children and adolescents: a pilot study. (11311929)
2001
44
Intermittent explosive disorder. (11122935)
2000
45
DSM-IV intermittent explosive disorder: a report of 27 cases. (9590677)
1998
46
Hypothalamic lesions and intermittent explosive disorder. (1627961)
1992
47
The diagnosis of intermittent explosive disorder in violent men. (2039850)
1991
48
Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient. (3667542)
1987
49
Therapeutic use of propranolol for intermittent explosive disorder. (3546964)
1987
50
Metoprolol for intermittent explosive disorder. (4025634)
1985

Variations for Intermittent Explosive Disorder

About this section

Expression for genes affiliated with Intermittent Explosive Disorder

About this section
Search GEO for disease gene expression data for Intermittent Explosive Disorder.

Pathways for genes affiliated with Intermittent Explosive Disorder

About this section

Pathways related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

(show all 11)
idSuper pathwaysScoreTop Affiliating Genes
1
Sympathetic Nerve Pathway (Pre- and Post- Ganglionic Junction)53
9.9CHRFAM7A, CHRNA7
2
Sympathetic Nerve Pathway (Neuroeffector Junction)53
9.3ADRB1, NPY
3
G alpha (s) signalling events57
9.2ADRB1, CGA, HTR7
4
Calcium signaling pathway31
8.6ADRB1, CHRFAM7A, CHRNA7, HTR2A, HTR7
5
SIDS Susceptibility Pathways39
8.4CHRFAM7A, CHRNA7, HTR1A, HTR2A, SLC6A4, TPH1
6
cAMP signaling pathway31
Show member pathways
8.3ADRB1, HTR1A, HTR1B, NPY
7
Monoamine GPCRs39
Show member pathways
8.3ADRB1, HTR1A, HTR1B, HTR2A, HTR7
8
CREB Pathway55
Show member pathways
8.0CHRFAM7A, CHRNA7, HTR1A, HTR1B, HTR2A, HTR7
9
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics53
8.0HTR1A, HTR1B, HTR2A, HTR7, SLC6A4, TPH1
10
Circadian entrainment31
Show member pathways
7.3CHRFAM7A, CHRNA7, HTR1A, HTR1B, HTR2A, HTR7
11
Peptide ligand-binding receptors57
Show member pathways
6.6ADRB1, CGA, CHRFAM7A, CHRNA7, HTR1A, HTR1B

GO Terms for genes affiliated with Intermittent Explosive Disorder

About this section

Biological processes related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of organ growthGO:004662110.4CGA, SLC6A4
2regulation of hormone secretionGO:004688310.1HTR1A, HTR2A
3vasoconstrictionGO:004231010.1HTR1A, SLC6A4
4adenylate cyclase-inhibiting serotonin receptor signaling pathwayGO:000719810.0HTR1A, HTR1B
5regulation of behaviorGO:005079510.0HTR1A, HTR1B
6temperature homeostasisGO:00016599.8ADRB1, HTR2A
7smooth muscle contractionGO:00069399.6HTR2A, HTR7
8circadian rhythmGO:00076239.1HTR7, SLC6A4, TPH1
9feeding behaviorGO:00076318.9HTR1B, NPY

Sources for Intermittent Explosive Disorder

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z